| Literature DB >> 20433769 |
Geerten-Has E Tjakkes1, Jan-Jaap Reinders, Elisabeth M Tenvergert, Boudewijn Stegenga.
Abstract
OBJECTIVES: As impact of literature concerning this subject is scarce, the objectives of this study were to assess whether the Health Related Quality of Life (HRQoL) is decreased in patients with painful temporomandibular disorders as compared to the HRQoL in the general population, and to evaluate to what extent pain duration affects HRQoL.Entities:
Mesh:
Year: 2010 PMID: 20433769 PMCID: PMC2876110 DOI: 10.1186/1477-7525-8-46
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Distribution of age, RDC diagnoses medication usage and coinciding chronic pain disorders among the three subgroups.
| Group | |||
|---|---|---|---|
| 1 | 2 | 3 | |
| Total | 15 | 16 | 64 |
| Female/male | 1/14 | 3/13 | 1/63 |
| Age (sd) | 37.6 (14.4) | 37.5 (14.1) | 41.6 (12.5) |
| n | n | n | |
| Group I | 3 | 8 | 20 |
| Group II | 0 | 0 | 3 |
| Group III | 5 | 7 | 24 |
| Group I + group II | 0 | 0 | 4 |
| Group I + group III | 5 | 0 | 12 |
| Group II + group III | 2 | 1 | 1 |
| Paracetamol | 0 | 1 | 7 |
| NSAID | 1 | 0 | 3 |
| Tricyclic antidepressant | 1 | 5 | 6 |
| Tricyclic antidepressant + paracetamol | 1 | 0 | 0 |
| Tricyclic antidepressant + NSAID | 0 | 0 | 2 |
| NSAID + opioid | 0 | 0 | 2 |
| Rheumatoid arthritis | 0 | 2 | 1 |
| Hernia | 0 | 0 | 1 |
| Back pain | 0 | 0 | 1 |
Group 1: Myofascial pain
Group 2: Disc displacement
Group 3: Arthralgia/osteoarthritis/osteoarthrosis
NSAID: Non-steroidal anti-inflammatory drug
SF-36 and GHQ scores in three groups of orofacial pain patients and reference values.
| reference | 1 | 2 | 3 | |
|---|---|---|---|---|
| Scale | Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) |
| SF-36 PFa | 83.0 (22.8) | 92.1 (8.1)*3 | 74.2 (33.1) | 72.3 (25.7)*1 |
| SF-36 RPa | 76.4 (36.3) | 54.2 (38.1) | 71.2 (3.6) 3 | 41.2 (39.7)*2 |
| SF-36 BPa | 74.9 (23.4) | 66.1 (20.4)3 | 53.2 (27.5)* | 48.5 (19.7)*1 |
| SF-36 GHa | 70.7 (20.7) | 53.0 (23.4)* | 55.8 (18.7)* | 54.4 (20.6)* |
| SF-36 VTa | 68.8 (19.3) | 52.9 (14.9)* | 49.3 (21.6)* | 55.2 (19.4)* |
| SF-36 SFa | 84.0 (22.4) | 74.0 (22.9) | 66.0 (29.2)* | 66.7 (23.4)* |
| SF-36 REa | 82.3 (32.9) | 66.7 (31.8) | 81.0 (55.0) | 80.9 (34.1) |
| SF-36 MHa | 76.8 (17.4) | 66.4 (12.5) | 60.6 (17.9)3 | 73.2 (13.0)2 |
| GHQAb | 6.2 | 6.7 (4.1) | 6.3 (4.1) | 8.2 (4.0)* |
| GHQBb | 5.8 | 2.8 (2.1)2 | 7.5 (3.6)1 | 5.9 (4.4) |
| GHQCb | 7.0 | 6.6 (1.8) 3 | 8.2 (3.3) | 8.3 (2.3)*1 |
| GHQDb | 1.6 | 0.8 (1.8) | 2.7 (3.5) | 1.9 (3.0) |
Values in mean (standard deviation, * p < 0.05 from reference values, in superscript the group to which the value is statistically different; reference values from a Aaronson et al.[19], b Koeter & Ormel [23].
(PF, physical functioning; RP, Role limitations physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role limitations emotional; MH, mental health; SD, standard deviation; GHQA, somatic symptoms; GHQB, anxiety and insomnia; GHQC, social dysfunction; GHQD, severe depression; P, P-value)
1. group with complaints of one year or shorter
2. group with complaints within 1 and 3 years
3. group with complaints longer than 3 years.
FIRS, HADSA and HADSD scores (standard deviation) for three groups.
| Group | |||
|---|---|---|---|
| 1 | 2 | 3 | |
| score | |||
| FIRS (sd) | 2.4 (1.1) | 2.6 (2.0) | 3.3 (1.6) |
| HADS A (sd) | 3.3 (1.8)2,3 | 6.4 (4.1)1 | 5.0 (3.6)1 |
| HADS D (sd) | 1.6 (1.1)2,3 | 6.2 (4.2)1,3 | 3.5 (3.1)1,2 |
1.: group with complaints of one year or shorter
2.: group with complaints within 1 and 3 years
3.: group with complaints longer than 3 years.
(FIRS; functional impairment rating score, HADSA; anxiety, HADSD; depression. In superscript the group to which the value is statistically different)
Figure 1The effect of duration of symptoms on psychosocial factors. From Okeson [6]. Used with permission.